Serge Guzy Combining interoccasion variability and mixture within a MCPEM framework
|
M. Tod (1), B. Blanchet (2), A. Astier (2), A. Hulin (2) Steady-state Equation for the Bicompartmental Model with Gamma Absorption. Application to Mycophenolate PK in Renal Transplant Patients
|
Mike Dunlavey Next-Generation Modeling Language
|
Iñaki F. Trocóniz (1), Raymond Miller (2), Mats O. Karlsson (3) Modelling Overdispersion and Markovian Features in Count Data
|
Clare Gaynor (1), Adrian Dunne (1) and John Davis (2) An assessment of prediction accuracy of two IVIVC modelling methodologies.
|
RJ Bauer (1), S Guzy (1), CM Ng (2) A Comparison of Estimation Methods in Nonlinear Mixed-effect Model for Population Pharmacokinetic-pharmacodynamic Analysis
|
Ihab G. Girgis, Tom Schaible, Partha Nandy, Filip De Ridder, Jeffrey Mathers, and Surya Mohanty Parallel Bayesian Methodology for Population Analysis
|
Matthews, I and Aarons, L Sensitivity analysis of a mixture model to determine genotype/phenotype
|
Didier Concordet, Djalil Chafaï How to estimate population variance matrices with a Prescribed Pattern of Zeros?
|
K.H. Liesenfeld, J. Stangier, H.G. Schaefer, A. Staab How can routinely collected comedication information from phase II/III trials be used for screening of potential effects on model parameters? A case study with the oral direct thrombin inhibitor Dabigatran etexilate
|
Thaddeus Grasela, PharmD, PhD The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process
|
Callies Sophie, Andre Valerie, Vick Andrew-Mark, Graff Jeremy, Patel Bharvin, Brail Leslie, Lahn Michael Modelling pharmacokinetic and pharmacodynamic properties of second generation antisense-oligonucleotides (ASOs).
|
Ng CM (1), Bauer RJ (2), Beeram M (1), Takimoto CH (1), Lin C (1), Patnaik A (1) A Systematical Approach to Bridge the Two-Stage Parametric Expectation Maximization Algorithm and Full Bayesian Three-Stage Hierarchical Nonlinear Mixed Effect Methods in Complex Population Pharmacokinetic/Pharmacodynamic Analysis: Troxacitabine-induced Neutropenia in Cancer Patients
|
Pankaj Gupta, Matthew M Hutmacher, Bill Frame and Raymond Miller A new approach for population pharmacokinetic data analysis under noncompliance
|
Stefaan Rossenu (1), Clare Gaynor (2), An Vermeulen (1), Adrian Dunne (2) and Adriaan Cleton (1) A mixture distribution approach to IVIVC modeling of a dual component drug delivery system
|
J. Areberg, L.E. Broksø Kyhl Simultaneous Population Pharmacokinetic Modelling of Parent Compound and Metabolite in Plasma and Urine for a New Drug Candidate
|
C.Crepin(1), E.Fuseau(1), M.Portugal(2), D.Humilier(2) Elimination of anti-epileptic compounds in Marseille aquatic environment from private hospital effluent - modelling versus measurements
|
Ihab G. Girgis, Vivek Viswanathan, Partha Nandy, and Surya Mohanty Interactive Graphical Visualization Tool for Safety Data Screening
|
Matthew M Hutmacher, Anand Vidyashankar, Debu Mukherhjee Comparing Minimum Hellinger Distance Estimation (MHDE) and Hypothesis Testing to Traditional Statistical Analyses – a Simulation Study
|
Stacey Tannenbaum (1), Gene Williams (2), He Sun (3), I. Peter Lee (2), Lawrence Lesko (2), and Robert Temple (2) A Comparison of Fixed Dose-Controlled (FD) versus Pharmacokinetic Modified Dose-Controlled (PKMD) Clinical Study Designs
|
Emilie Hénin (1,2), Véronique Trillet-Lenoir (1,2,3), Olivier Colomban (1,2), Michel Tod (1,2), Pascal Girard (1,2) Estimation of patient compliance from pharmacokinetic samples
|
Martin Bergstrand, Elodie Plan, Maria Kjellsson, Mats O Karlsson A comparison of methods for handling of data below the limit of quantification in NONMEM VI
|
Robert R. Bies1, Serge Guzy2, Joshua Sokoloski3, Laura Drewencki3, and Amy K. Wagner3. An MCPEM approach to understanding inter-animal and inter-treatment changes with in vivo striatal dopamine clearance in rats.
|